Phorbol 12,13-Dibutyrate

Subscribe to Selected New Research on Phorbol 12,13-Dibutyrate

128 relevant articles (5 outcomes, 10 trials/studies) found for this Bio-Agent

Description: A phorbol ester found in CROTON OIL which, in addition to being a potent skin tumor promoter, is also an effective activator of calcium-activated, phospholipid-dependent protein kinase (protein kinase C). Due to its activation of this enzyme, phorbol 12,13-dibutyrate profoundly affects many different biological systems.

Also Known As:

Phorbol-12,13-Dibutyrate; 12,13-Dibutyrate, Phorbol; Phorbol 12,13 Dibutyrate; Butanoic acid, 1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-9aH-cyclopropa(3,4)benz(1,2-e)azulene-9,9a-diyl ester, (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9beta,9aalpha))-

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Phorbol 12,13-Dibutyrate: 128

Experts

1.	Kagaya, Y: 1 article (03/2000)
2.	Ido, T: 1 article (03/2000)
3.	Chida, M: 1 article (03/2000)
4.	Watanabe, J: 1 article (03/2000)
5.	Fukuchi, M: 1 article (03/2000)
6.	Tezuka, F: 1 article (03/2000)
7.	Namiuchi, S: 1 article (03/2000)
8.	Takahashi, C: 1 article (03/2000)
9.	Shirato, K: 1 article (03/2000)
10.	Yamane, Y: 1 article (03/2000)

Related Diseases

1.	Neoplasms (Cancer) 05/15/2007 - "Phorbol 12,13-dibutyrate (PDBu, 100 nM), which enhanced activities of PKC-alpha, increased cancer cell proliferation and attenuated VIN (1 microM)-induced cytotoxicity" 01/01/1991 - "Long-term (3 months) treatment of IE7 cells with 500 ng/ml phorbol 12,13-dibutyrate (PDB) resulted in a 4-fold reduction in total PKC activity and increase in the tumor cell metastatic ability" 11/15/1989 - "It was found that the maximal binding capacity of [20-3H]phorbol-12,13-dibutyrate of the tumor promoter-dependent cells is lower than that of the independent cells with similar affinities of the two cell lines" 09/01/1988 - "Phorbol-12,13-dibutyrate (PDBu) is a tumor promoter that activates a variety of cellular responses, including proliferation" 09/01/1988 - "Use of phorbol-12,13-dibutyrate as a mitogen in the cytogenetic analysis of tumors with low mitotic indexes." Get all the results and reference details, order at left...
2.	Ischemia 01/01/1992 - "One month after ischemia, [3H]phorbol 12,13-dibutyrate binding showed significant reduction only in the striatum and the hippocampal CA1 sector where severe neuronal damage was seen morphologically" 08/28/1989 - "Binding of [3H]inositoltrisphosphate and [3H]phorbol 12,13-dibutyrate in rat hippocampus following transient global ischemia: a quantitative autoradiographic study." 01/01/1992 - "A significant elevation in the number of [3H]phorbol 12,13-dibutyrate binding sites was still seen in the dentate molecular layer one month after ischemia" 01/01/1992 - "Interestingly, dentate molecular layer which was resistant to ischemia showed a significant elevation in the number of [3H]phorbol 12,13-dibutyrate binding sites" 01/01/1992 - "3H]Phorbol 12,13-dibutyrate binding in selectively vulnerable areas showed no significant change 1-24 h after ischemia except for a transient decline in a few regions" Get all the results and reference details, order at left...
3.	Lymphoma (Lymphomas) 04/01/1995 - "Focusing on high-quality analyzable metaphases, the best results were found in seven of 13 cases with lymphomas and five of six patients with ALL in the cultures supplemented with phorbol-12,13-dibutyrate" Get all the results and reference details, order at left...
4.	Leukemia 09/01/1983 - "The influence of cellular lipid composition on the specific binding of [20-3H]phorbol-12,13-dibutyrate to intact human promyelocytic leukemia cells was investigated" 02/18/1992 - "PKC was isolated and purified from human leukemia ML-1 cells, and the enzyme activity was shown to be activated by the tumor promoters 12-O-tetradecanoylphorbol-13-acetate (TPA) and phorbol-12,13-dibutyrate (PDBu)" 02/05/1988 - "Treatment of human promyelocytic leukemia cells (HL-60) with phorbol 12-myristate 13-acetate or phorbol 12,13-dibutyrate (PDBu) caused a rapid decrease in transcription of the c-myc protooncogene" 03/01/1981 - "Binding of [20-3H]phorbol 12,13-dibutyrate ([3H]PDB) to intact human promyelocytic leukemia cells susceptible (HL-60) or resistant (R-35) to phorbol ester-induced differentiation was characterized" 03/01/1981 - "Down regulation of specific binding of [20-3H]phorbol 12,13-dibutyrate and phorbol ester-induced differentiation of human promyelocytic leukemia cells." Get all the results and reference details, order at left...
5.	Neuroblastoma 01/01/1988 - "The binding characteristics of [3H]phorbol-12,13-dibutyrate ([3H]PDBu) in mouse neuroblastoma N1E-115 cells were studied" 09/01/1983 - "The mouse skin tumor promoter phorbol-12,13-dibutyrate (PDBU) reversibly enhanced neurite outgrowth in SH-SY5Y human neuroblastoma cells, whether serum was present or absent" 01/01/1988 - "Regulation of [3H]phorbol-12,13-dibutyrate binding sites in mouse neuroblastoma cells: simultaneous down-regulation by phorbol esters and desensitization of their inhibition of muscarinic receptor function." 01/01/1995 - "Whereas PF(peak) starts to rise at -50 mV and reaches a maximum at +40 to +50 mV, PF(ss) only begins to rise appreciably at around 0 mV and is still increasing at +100 mV. This differs from observations on vertebrate excitable tissues where the persistent Na+ current tums on in the threshold region and saturates at around 0 mV. Schmitt and Meves (Pflugers Arch (1993) 425, 134-139) recorded M current, a non-inactivating K+ current, from NGI08-15 neuroblastoma x glioma hybrid cells, voltage-clamped in the whole-cell mode, and studied the effects of phorbol 12,13-dibutyrate (PDB), an activator of protein kinase C (PKC), and arachidonic acid (AA)" 04/02/2004 - "In this study, we observed that: (a) Phorbol 12,13-dibutyrate (PDBu)-stimulated APP secretion in cultured SH-SY5Y neuroblastoma and fibroblast cells was blocked by EGTA and calpain inhibitors in a concentration-dependent manner, but not by other protease inhibitors" Get all the results and reference details, order at left...
53 Diseases and 128 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	phorbol
2.	Forskolin
3.	Inositol (Myoinositol)
4.	Epinephrine (Adrenaline)
5.	Cyclic AMP (AMP, Cyclic)
6.	Protein Kinase C
7.	Phorbol Esters
8.	Epidermal Growth Factor (EGF)
9.	Morphine (MS Contin)
10.	Protein Kinases (Protein Kinase)
125 Drugs and Important Bio-Agents and 104 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Immunotherapy
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>